Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
140 participants
OBSERVATIONAL
2020-01-29
2023-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to the French guidelines, neostigmine, a cholinesterase inhibitor, should be used to reverse a residual neuromuscular blockade at a dose of 0.4 mg/kg of total body weight in non-obese patients. In morbidly-obese patients, with the modification of the fat/lean mass ratio, the optimal dose of neostigmine is non-consensual. To calculate the dose of neostigmine, some anesthesiologists use the total body weight, others use the ideal body weight and others use the adjusted body weight.
Due to this practice variability, It may be useful to observe the mean time to recovery of neuromuscular blockade and side effects after pharmacological reversal according to the dosage of neostigmine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions
NCT02118844
Deep Versus Moderate Neuromuscular Blockade in Bariatric Surgery
NCT06553066
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
NCT02300168
Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery
NCT04709406
Paragastric Autonomic Blockade to Prevent Visceral Pain After Laparoscopic Sleeve Gastrectomy
NCT05353426
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ideal Body Weight
groups of patients divided according to neostigmine dose weight, ideal body weight (IBW)
NO INTERVENTION, it is an observational study
No intervention
Total Body Weight
groups of patients divided according to neostigmine dose weight, total body weight (TBW),
NO INTERVENTION, it is an observational study
No intervention
Adjusted Body Weight
groups of patients divided according to neostigmine dose weight, , adjusted body weight (ABW)
NO INTERVENTION, it is an observational study
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NO INTERVENTION, it is an observational study
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any elective bariatric surgery
* Neuromuscular blockade with rocuronium
* Maintenance of anesthesia with a halogenated agent
* Free patient, without guardianship or subordination
* Patients with a social security coverage
* No opposition given by the patient after clear and fair information
Exclusion Criteria
* Emergency surgery,
* Severe renal and / or hepatic insufficiency,
* Persons benefiting from enhanced protection, namely pregnant women, breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection and finally sick people in emergency situation.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Poitiers
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A02647-50
Identifier Type: OTHER
Identifier Source: secondary_id
NEOCURE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.